Geron

GERON CORP

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Wall Street_Dow

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ENVB

FLYW

GERN

MULN

PRCH

Dow Dips Over 100 Points; TJX Earnings Top Views

Nasdaq index

VERO

Nasdaq Surges 150 Points; Lowe&#39;s Posts Upbeat Earnings

movers image

Movers

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNFR

FEDU

INTC

IOBT

KROS

LITB

MNOV

MRVL

MSGM

NVAX

NVCR

NVMI

PCVX

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Geron Corp

Legal

Press Releases

GERN Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges GERN Investors with Losses to Contact the Firm

Shareholders of Geron Corporation Should Contact The Gross Law Firm Before May 12, 2025 to Discuss Your Rights - GERN

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers - GERN

ROSEN, A LONGSTANDING LAW FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN

Investors in Geron Corporation Should Contact The Gross Law Firm Before May 12, 2025 to Discuss Your Rights – GERN

GERN Stockholders Should Contact Robbins LLP for Information About How They Can Lead the Geron Corporation Class Action

GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

GERN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Class Action Announcement for Geron Corporation Investors:  A Securities Fraud Class Action Lawsuit Was Filed Against Geron Corporation - Contact Kessler Topaz Meltzer & Check, LLP

Ardelyx

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dyne Therapeutics

89bio

GRAIL

Gyre Therapeutics

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Needham

Scotiabank

Stifel

Barclays

B. Riley Securities

Comments

Geron

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga